HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Oger, J. Articles by Paty, D. W. Search for Related Content PubMed PubMed Citation Articles by Oger, J. Articles by Paty, D. W.

Multiple sclerosis

In relapsing patients, immune functions vary with disease activity as assessed by MRI

University of British Columbia, Department of Medicine, Division of Neurology and Multiple Sclerosis Clinic, Vancouver, BC, Canada.

We have serially studied immunoglobulin G secretion in vitro, natural killer cell function, and concanavalin A-induced suppression in a group of seven patients with relapsing-remitting multiple sclerosis. In two patients, the development of a large clinically asymptomatic MRI lesion was accompanied by reductions in natural killer cell function, immunoglobulin G secretion in vitro (after pokeweed mitogen stimulation), and concanavalin A-induced suppression without parallel change in lymphocyte markers. We did not see this type of change in matched controls nor in stable multiple sclerosis studied serially. When clinical attacks appeared, there was no significant change in immune function. We conclude that changes in immune function correlate well with the activity of the disease as recognized by MRI. We suspect that decreased natural killer cell function, immunoglobulin G secretion in vitro, and concanavalin A-induced suppression are secondary to the large lesions recognized by MRI.

Address correspondence and reprint requests to Dr. Oger, Division of Neurology, University Hospital, 2211 Wesbrook Mall, Vancouver, British Columbia V6T 2B5, Canada.

Supported by grants from the Multiple Sclerosis Society of Canada, the Medical Research Council of Canada, the British Columbia Health Care Research Foundation, and the Jacob W. Cohen Fund for MS Research.

Received September 15, 1987. Accepted for publication in final form May 19, 1988.

This article has been cited by other articles:

				A. T. Reder and J. J. Oger Anti-myelin oligodendrocyte glycoprotein antibodies in multiple sclerosis Neurology, June 8, 2004; 62(11): 1922 - 1923. [Full Text] [PDF]

				S. J. Khoury, C. R. G. Guttmann, E. J. Orav, R. Kikinis, F. A. Jolesz, and H. L. Weiner Changes in Activated T Cells in the Blood Correlate With Disease Activity in Multiple Sclerosis Arch Neurol, August 1, 2000; 57(8): 1183 - 1189. [Abstract] [Full Text] [PDF]

				A. Vora, D. Kidd, D. Miller, G. Perkin, R. Hughes, B. Ellis, D. Dumonde, and K. Brown Lymphocyte-endothelial cell interactions in multiple sclerosis: disease specificity and relationship to circulating tumour necrosis factor-{alpha} and soluble adhesion molecules Multiple Sclerosis, June 1, 1997; 3(3): 171 - 179. [Abstract] [PDF]

				P. S. Sorensen, B. Wanscher, K. Schreiber, M. Blinkenberg, C.V. Jensen, and M. Ravnborg A double-blind, cross-over trial of intravenous immunoglobulin G in multiple sclerosis: Preliminary results Multiple Sclerosis, April 1, 1997; 3(2): 145 - 148. [Abstract] [PDF]

				P. S. Sorensen Intravenous immunoglobulin G therapy: effects of acute and chronic treatment in multiple sclerosis Multiple Sclerosis, June 1, 1996; 1(6): 349 - 352. [Abstract] [PDF]

				D. E Goodkin MS clinical trial design for the future Multiple Sclerosis, June 1, 1996; 1(6): 393 - 399. [Abstract] [PDF]

				D. E. Goodkin, R. A. Rudick, and J. S. Ross The Use of Brain Magnetic Resonance Imaging in Multiple Sclerosis Arch Neurol, May 1, 1994; 51(5): 505 - 516. [Abstract] [PDF]

				D. Maimone, A. T. Reder, F. Finocchiaro, and E. Recupero Internal Capsule Plaque and Tonic Spasms in Multiple Sclerosis Arch Neurol, April 1, 1991; 48(4): 427 - 429. [Abstract] [PDF]